A. A. Pozdniakova

A. A. Pozdniakova

Auto-generated profile, based on publicly available information

A. A. Pozdniakova

Sechenov First Moscow State Medical University (Sechenov University)

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 February 2023 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
SASergey Avdeev
Sergey Avdeev
VGVilya Gaynitdinova
Vilya Gaynitdinova
APA A Pozdniakova
A A Pozdniakova
AVAnna Vlasenko
Anna Vlasenko
TGT I Gneusheva
T I Gneusheva
IBI V Baytemerova
I V Baytemerova
Background. Mortality and COVID-19 related factors are thoroughly analyzed. Given the large number of hospitalized patients, the potential short- and long-term COVID-19 related complications, further research is needed on the possible consequences of hospitalization, especially in higher-risk patients, after prolonged hospitalization and intensive care admission. Aim. To study the clinical course and outcomes of severe COVID-19 in elderly patients with asthma at the hospital and early post-hospital stages. Materials and methods. The study included 131 elderly patients (WHO, 2020) 60 years old, n=131 with asthma, hospitalized for severe COVID-19. Of these, 86 (65.6%) patients survived, 30 (22.9%) died in the hospital, and 15 (14.9%) patients died after discharge from the hospital (in the 90-day post-hospital period). COVID-19 was confirmed by laboratory tests (SARS-CoV-2 PCR RNA test) and/or clinically and radiologically. All patients had a documented history of asthma. Patients were followed up during the hospital stay and for 90 days after discharge. Results. Comparison of outcomes showed that in the groups of patients with a fatal outcome (regardless of the stage), the Charlson comorbidity index, respiratory rate, extent of lung damage assessed by computed tomography, the absolute leukocyte and neutrophil number and the ratio of neutrophils to lymphocytes were statistically significantly higher. The absolute number of eosinophils was lower in these groups. In the group of patients who died during hospitalization, severe (IVV) asthma (p=0.03), steroid use during the previous year (p=0.02), chronic heart failure with a reduced ejection fraction (p=0.009) were more common, and atopic asthma phenotype was less common (p=0.02). In those who died after discharge, more common were non-invasive ventilation and diabetes mellitus (p0.001). The multivariate regression analysis model revealed the most significant predictors of mortality at the hospital and early post-hospital stages. Conclusion. Adverse outcomes of severe COVID-19 in elderly patients with asthma include hospital and post-hospital mortality. The most significant predictors of mortality are the comorbidity index and low eosinophil count. Hospital mortality is associated with a higher ratio of neutrophils to lymphocytes and lower total protein levels; early (90-day) post-hospital mortality is associated with extensive lung damage shown by computed tomography and diabetes mellitus.

19 January 2023 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
VGVilya Gaynitdinova
Vilya Gaynitdinova
SASergey Avdeev
Sergey Avdeev
APA. A. Pozdniakova
A. A. Pozdniakova
AVAnna Vlasenko
Anna Vlasenko
TGT. Yu. Gneusheva
T. Yu. Gneusheva
DAD. U. Allaberdina
D. U. Allaberdina
Introduction. The role of comorbid conditions in susceptibility to SARS-CoV-2 infection and the severity of associated COVID-19 disease has been an area of ongoing research since the pandemic began.Objective. To evaluate the impact of elderly asthma on the clinical course and outcomes of severe COVID-19.Materials and methods. Elderly patients (WHO, 2020) (> 60 years, n = 131) with bronchial asthma (BA) hospitalized for severe COVID-19 were included in the study. The presence of COVID-19 was confirmed by laboratory tests (PCR smear) and/or clinical and radiological examinations. All patients had a history of a confirmed diagnosis of bronchial asthma (GINA, 2020). Follow-up was performed at the hospital stage and for 90 days after discharge from the hospital.Results. In the groups of patients with lethal outcome (regardless of the stage) there were statistically significantly higher Charlson index, respiratory rate, CT lung lesion volume, leukocyte, neutrophil and neutrophil to lymphocyte ratios, lower absolute eosinophil count. In the group of patients who died during hospitalization, severe (IV–V) asthma (p = 0.03), steroid use during the previous year (p = 0.02), chronic heart failure (p = 0.009), and the atopic asthma phenotype was less common (p = 0.02). Those who died in the 90-day posthospital period had greater lung lesion volume on CT scan, and diabetes mellitus was more common (p < 0.001). The most significant predictors of mortality were identified.Conclusion. The common most significant predictors of hospital and 90-day posthospital mortality in older patients with bronchial asthma were comorbidity index and lower eosinophil levels. Hospital mortality is further characterized by a higher neutrophil to lymphocyte ratio and lower total protein; 90-day posthospital mortality by the amount of lung damage on CT scan and the presence of diabetes mellitus.

14 July 2026 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
TGT. Yu. Gneusheva
T. Yu. Gneusheva
VGVilya Gaynitdinova
Vilya Gaynitdinova
APA. A. Pozdnyakova
A. A. Pozdnyakova
EAE. S. Aynetdinova
E. S. Aynetdinova
YWYu. Wang
Yu. Wang
Introduction . Concomitant chronic obstructive pulmonary disease (COPD) is one of the most important risk factors for the development of COVID-associated lung damage. Aim . To study risk factors for the development of severe COVID-associated lung damage in patients with COPD. Materials and methods . A retrospective single-center comparative study was conducted. The study included 154 patients hospitalized for COVID-19, of which 103 patients had COPD. The comparison group consisted of patients (n = 51) without COPD and smoking history on the case-control principle. The presence of COVID-19 was confirmed by laboratory tests and/or clinically and radiologically. The dynamics of clinical and laboratory-instrumental indicators were evaluated from the first to the seventh day of observation. Results. In the COVID-19 group without COPD, the proportion of patients with lung damage CT 1–2 and CT 3–4 was 47% (18/38), in the COVID-19 and COPD group – 38% (39/103); no statistically significant differences were found (p = 0.41). Lung damage CT 3–4 regardless of the presence/absence of COPD was statistically significantly associated with older age, higher body mass index, coronary artery disease, increased levels of blood pressure, respiratory rate, neutrophils, CRP, AST, LDH, and decreased SpO 2 level. In the group of patients with COVID-19 and COPD, lung damage CT 3–4 was associated with higher values of these indicators than in the group of patients with COVID-19 without COPD: the threshold value of leukocytes in the COVID-19 group without COPD was 5.6 × 10 9 /L versus 10.9 × 10 9 /L in patients with COVID-19 and COPD, the threshold value of neutrophils – 4.2 × 10 9 /L and 9.3×10 9 /L, the threshold value of the neutrophil/lymphocyte ratio – 5.8 and 11.3. Lung damage CT 3–4 in patients with COVID-19 and COPD was associated with higher mMRC scores (odds ratio [OR] = 2.75 [95% CI: 1.09–6.92] for 3 points versus 2, OR = 4.24 [95% CI: 1.26–14.3] for 4 points versus 2), higher CAT scores (OR = 4.87; 95% CI: 1.88–13.53 for CAT above 18 points) and mixed COPD phenotype (OR = 2.94; 95% CI: 1.10–8.07) versus bronchitic (p = 0.045). Conclusion . Severe COVID-associated lung damage (CT 3–4) develops under the influence of general factors (age, obesity, inflammation, hypoxemia), but in patients with COPD it occurs against the background of more pronounced systemic inflammation and is aggravated by symptoms of the underlying disease.

20 March 2025 in Journal of Respiratory Medicine
Verified
Journal Article
Closed access
APA.A. Pozdnyakova
A.A. Pozdnyakova
VGVilya Gaynitdinova
Vilya Gaynitdinova
ZMZ.M. Merzhoeva
Z.M. Merzhoeva
GNG.S. Nuralieva
G.S. Nuralieva
ESE.S. Sokolova
E.S. Sokolova
SASergey Avdeev
Sergey Avdeev
There is a significant decrease in the eosinophil level of patients’ peripheral blood in COVID-19, and in most of them — at an early stage, regardless of the disease’s severity. It is believed that patients with bronchial asthma have a lower risk of adverse outcomes of COVID-19, and eosinophilia, both in patients with and without asthma, is associated with a reduced risk of mortality. Objective. To study the relationship of eosinophil level with the outcomes of severe COVID-19 in bronchial asthma of the elderly. Material and methods. The study included elderly patients (>60 years old (according to WHO classification, 2020), n=76) with documentally confirmed history of bronchial asthma (according to GINA criteria, 2020), hospitalized for severe COVID-19. Presence of COVID-19 was confirmed by laboratory tests (polymerase chain reaction) and/or clinically and radiologically. The patients were monitored at the hospital stage and within 1 month after discharge from the hospital. Calculation of odds ratio and 95% confidence intervals (95% CI) was done using single-factor and multi-factor logistic regression (IBM SPSS Statistics v. 22 application software package). Results. Analysis of eosinophil level depending on the disease’s outcome (survived/died) has shown that the median of eosinophil level in the group of survived patients was 30 [10; 100] (95% CI 13—60) cells/µL, and in the group of deceased — 16.5 [9; 39] (95% CI 11—29) cells/µL, the differences were statistically significant (p=0.04). The level of eosinophils above 100 cells/µL is associated with a favorable outcome of the disease, and the chance of survival at such eosinophil level is 13.5 (95% CI 1.6—242) times higher than at the level of eosinophils 100 cells/µg) was associated with lower glucose level (<7 mmol/L), lactate dehydrogenase (LDH) (<450 U/L) and respiratory rate (<23 per minute), thus the relationship between the chance of survival and eosinophil level remained statistically significant — OR 32.1 (95% CI 1.1—141) (p=0.04). Despite the existing relationship between the level of eosinophils and mortality, the relationship between the absolute number of eosinophils and the duration of hospitalization was not revealed. Conclusion. Elevated level of eosinophils in bronchial asthma of the elderly and severe COVID-19 is associated with a favorable outcome of the disease.

1 January 2025 in Doctor.Ru
Verified
Journal Article
Open access
SASergey Avdeev
Sergey Avdeev
RMRussian Federation Moscow
Russian Federation Moscow
TGT.YU. Gneusheva
T.YU. Gneusheva
VGVilya Gaynitdinova
Vilya Gaynitdinova
APA.A. Pozdnyakova
A.A. Pozdnyakova
DAD.U. Allaberdina
D.U. Allaberdina
Aim. To study the clinical course of COVID-19 in patients with chronic obstructive pulmonary disease (COPD). Design. A retrospective, single-center, longitudinal study. Materials and methods. The study included 154 patients hospitalized for COVID-19, including 103 with COPD and 51 patients without COPD and a smoking history. The presence of COVID-19 was confirmed by laboratory tests (smear on the RNA of the SARS-CoV-2 virus from the upper respiratory tract by polymerase chain reaction) and/or clinically and radiologically. The diagnosis of patients with COPD was documented in accordance with the criteria of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2020. All patients underwent demographic assessment, measurement of body mass index, evaluation of disease symptoms, and objective and instrumental studies. Objective laboratory tests included general and biochemical blood tests, assessment of C-reactive protein levels upon admission and in dynamics, and coagulation studies. Instrumental studies included computed tomography of chest organs. Pulse oximetry was used to measure blood oxygen saturation and detect respiratory failure. These measurements were used to assess the severity of hypoxia. Results. Patients with COVID-19 and COVID-19 and COVID-19 without COPD were comparable by age, severity of lung injury and anti-IL6 therapy. In the majority of cases COPD in patients with COVID-19 has occurred with frequent exacerbations, had pronounced clinical manifestations and was presented by bronchitic and mixed phenotypes. The clinical features of COVID-19 in patients with COPD include statistically significantly lower levels of oxygen saturation (SpO2), total protein, alanine aminotransferase, aspartate aminotransferase, and respiratory rate, as well as higher oxygen flow rate, white blood cell count, absolute neutrophil and eosinophil counts, D-dimer concentrations, and creatinine. In addition, there is a significant increase in the need for non-invasive ventilation and mortality in patients with COVID-19 and COPD. The precursors of deaths in the COVID-19 and COPD group were older age, excessive body mass, emphysema > 4.8% and associated diabetes mellitus. Conclusion. Since COPD occurs later in life and is often associated with other conditions, the combination of COVID-19 and COPD may have several negative interactions that can lead to a poor outcome from COVID-19. Additionally, thrombosis and coagulopathy are common in severe cases of both COVID-19 and COPD. It is therefore important to understand if pre-existing endothelial dysfunction in COPD patients increases their risk of vascular complications during COVID-19. Furthermore, research has shown that COPD is also associated with worse outcomes from COVID-19, regardless of age and other related conditions. Keywords: COVID-19, chronic obstructive pulmonary disease, phenotypes, emphysema, outcomes